Abstract
Rational design methodologies such as quantitative structure activity relationships (QSAR) have conventionally focused on screening through several drugs for their activity against a single target, either a bacterial protein or membrane. Recent concerns in drug design such as the development of drug resistance by membrane adaptation, or the undesirable damage to gut microbiota require a paradigm shift in activity prediction. A complementary approach capable of predicting the activity of a single drug against diverse targets, the diversity arising from bacterial adaptation or a heterogeneous composition with other helpful or harmful bacteria, is needed. As a first predictive step towards this goal, we develop a quantitative model for the activity of daptomycin on Streptococcus aureus strains with different membrane compositions, mainly varying in lysylation. The results of the predictions are good, and within the limits of the scarcely available data, hint at an interaction of daptomycin with the inner membrane. The complementary approach may in principle be extended to estimate the activity against gut bacterial membranes, when systematic data can be curated for training the model.